APA (7th ed.) Citation

Iwuji, C. C., Churchill, D., Bremner, S., Perry, N., To, Y., Lambert, D., . . . Geretti, A. M. (2020). A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): Study protocol for a randomised trial. BMC Infectious Diseases, 20(1), 1. https://doi.org/10.1186/s12879-020-05240-y

Chicago Style (17th ed.) Citation

Iwuji, Collins C., et al. "A Phase IV Randomised, Open-label Pilot Study to Evaluate Switching from Protease-inhibitor Based Regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in Integrase Inhibitor-naïve, Virologically Suppressed HIV-1 Infected Adults Harbouring Drug Resistance Mutations (PIBIK Study): Study Protocol for a Randomised Trial." BMC Infectious Diseases 20, no. 1 (2020): 1. https://doi.org/10.1186/s12879-020-05240-y.

MLA (9th ed.) Citation

Iwuji, Collins C., et al. "A Phase IV Randomised, Open-label Pilot Study to Evaluate Switching from Protease-inhibitor Based Regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in Integrase Inhibitor-naïve, Virologically Suppressed HIV-1 Infected Adults Harbouring Drug Resistance Mutations (PIBIK Study): Study Protocol for a Randomised Trial." BMC Infectious Diseases, vol. 20, no. 1, 2020, p. 1, https://doi.org/10.1186/s12879-020-05240-y.